Treatment with synthetic TRβ agonists KB-141 in ob/ob mice improves glucose tolerance and insulin sensitivity in a dose-dependent manner, supporting the potential of selective TRβ activation for anti-obesity, lipid-lowering, and antidiabetic therapy.522. This evidence concerns the gene THRB and Obesity.